» Articles » PMID: 32045384

Mesenchymal Stromal Cells Shape the MDS Microenvironment by Inducing Suppressive Monocytes That Dampen NK Cell Function

Overview
Journal JCI Insight
Date 2020 Feb 12
PMID 32045384
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Altered BM hematopoiesis and immune suppression are hallmarks of myelodysplastic syndrome (MDS). While the BM microenvironment influences malignant hematopoiesis, the mechanism leading to MDS-associated immune suppression is unknown. We tested whether mesenchymal stromal cells (MSCs) contribute to this process. Here, we developed a model to study cultured MSCs from patients with MDS (MDS-MSCs) compared with those from aged-matched normal controls for regulation of immune function. MDS-MSCs and healthy donor MSCs (HD-MSCs) exhibited a similar in vitro phenotype, and neither had a direct effect on NK cell function. However, when MDS- and HD-MSCs were cultured with monocytes, only the MDS-MSCs acquired phenotypic and metabolic properties of myeloid-derived suppressor cells (MDSCs), with resulting suppression of NK cell function, along with T cell proliferation. A MSC transcriptome was observed in MDS-MSCs compared with HD-MSCs, including increased expression of the ROS regulator, ENC1. High ENC1 expression in MDS-MSCs induced suppressive monocytes with increased INHBA, a gene that encodes for a member of the TGF-β superfamily of proteins. These monocytes also had reduced expression of the TGF-β transcriptional repressor MAB21L2, further adding to their immune-suppressive function. Silencing ENC1 or inhibiting ROS production in MDS-MSCs abrogated the suppressive function of MDS-MSC-conditioned monocytes. In addition, silencing MAB21L2 in healthy MSC-conditioned monocytes mimicked the MDS-MSC-suppressive transformation of monocytes. Our data demonstrate that MDS-MSCs are responsible for inducing an immune-suppressive microenvironment in MDS through an indirect mechanism involving monocytes.

Citing Articles

MSCs with upregulated lipid metabolism block hematopoietic stem cell differentiation via exosomal CTP-1A in MDS.

Yin C, Yan X, Ren J, Zhang C, Liu J, Wang Z Stem Cell Res Ther. 2025; 16(1):53.

PMID: 39920846 PMC: 11806692. DOI: 10.1186/s13287-025-04154-3.


Fate and long-lasting therapeutic effects of mesenchymal stromal/stem-like cells: mechanistic insights.

Hoseinzadeh A, Esmaeili S, Sahebi R, Melak A, Mahmoudi M, Hasannia M Stem Cell Res Ther. 2025; 16(1):33.

PMID: 39901306 PMC: 11792531. DOI: 10.1186/s13287-025-04158-z.


Natural products: promising therapeutics for targeting regulatory immune cells in the tumor microenvironment.

Song P, Song F, Shao T, Wang P, Li R, Chen Z Front Pharmacol. 2024; 15:1481850.

PMID: 39605905 PMC: 11598344. DOI: 10.3389/fphar.2024.1481850.


Ultralow-dose irradiation enables engraftment and intravital tracking of disease initiating niches in clonal hematopoiesis.

Lee K, Dissanayake W, MacLiesh M, Hong C, Yin Z, Kawano Y Sci Rep. 2024; 14(1):20486.

PMID: 39227700 PMC: 11372138. DOI: 10.1038/s41598-024-71307-4.


Sequential gene expression analysis of myelodysplastic syndrome transformation identifies HOXB3 and HOXB7 as the novel targets for mesenchymal cells in disease.

Yin C, Li Y, Zhang C, Zang S, Wang Z, Yan X BMC Cancer. 2024; 24(1):111.

PMID: 38254070 PMC: 10802074. DOI: 10.1186/s12885-024-11859-w.


References
1.
Fan S, Wang Y, Sheng N, Xie Y, Lu J, Zhang Z . Low expression of ENC1 predicts a favorable prognosis in patients with ovarian cancer. J Cell Biochem. 2018; 120(1):861-871. DOI: 10.1002/jcb.27447. View

2.
Huang J, Basu S, Zhao X, Chien S, Fang M, Oehler V . Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration. Blood Cancer J. 2015; 5:e302. PMC: 4450324. DOI: 10.1038/bcj.2015.17. View

3.
Spaggiari G, Moretta L . Cellular and molecular interactions of mesenchymal stem cells in innate immunity. Immunol Cell Biol. 2012; 91(1):27-31. DOI: 10.1038/icb.2012.62. View

4.
Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M . Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 2004; 22(3):377-84. DOI: 10.1634/stemcells.22-3-377. View

5.
Gao F, Chiu S, Motan D, Zhang Z, Chen L, Ji H . Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016; 7:e2062. PMC: 4816164. DOI: 10.1038/cddis.2015.327. View